Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/197869
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bafadhel, Mona | - |
dc.contributor.author | Faner, Rosa | - |
dc.contributor.author | Taillé, Camille | - |
dc.contributor.author | Russell, Richard E. K. | - |
dc.contributor.author | Welte, Tobias | - |
dc.contributor.author | Barnes, Peter J. | - |
dc.contributor.author | Agustí García-Navarro, Àlvar | - |
dc.date.accessioned | 2023-05-11T14:22:59Z | - |
dc.date.available | 2023-05-11T14:22:59Z | - |
dc.date.issued | 2022 | - |
dc.identifier.issn | 0905-9180 | - |
dc.identifier.uri | http://hdl.handle.net/2445/197869 | - |
dc.description.abstract | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms | - |
dc.format.extent | 13 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1183/16000617.0099-2022 | - |
dc.relation.ispartof | European Respiratory Review, 2022, vol. 31, p. 220099 | - |
dc.relation.uri | https://doi.org/10.1183/16000617.0099-2022 | - |
dc.rights | cc-by (c) Bafadhel, Mona et al., 2022 | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.source | Articles publicats en revistes (Biomedicina) | - |
dc.subject.classification | Asma | - |
dc.subject.classification | Corticosteroides | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | SARS-CoV-2 | - |
dc.subject.other | Asthma | - |
dc.subject.other | Adrenocortical hormones | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | SARS-CoV-2 | - |
dc.title | Inhaled corticosteroids for the treatment of COVID-19 | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 727736 | - |
dc.date.updated | 2023-05-11T14:22:59Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 9332994 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Biomedicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
727736.pdf | 588.79 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License